AmerisourceBergen
Customer Huddle #12

August 12, 2020

During the call, please submit questions via the Skype window.

Both audio and visuals are available through the Skype Meeting Broadcast link and are accessible via any browser, either PC or mobile.
Today’s Speaker

Keyvan Nekouei
Sr. Director, Account Experience & Clinical Services

Brad Tallamy
Sr. Director, Government Affairs

Sean McGowan
Sr. Director, Biosimilars

Michelle Jesse
Director, Biosimilars

During the call, please submit questions via the Skype Q&A window.

Both audio and visuals are available through the Skype Meeting Broadcast link and are accessible via any browser, either PC or mobile.
## Drug Shortage - Lupron

### PRODUCTS IMPACTED

<table>
<thead>
<tr>
<th>NDC CODE</th>
<th>DESCRIPTION</th>
<th>LUPRON CLASSIFICATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>0074-9694-03</td>
<td>LURPON DEPOT PED, 3MONTH, 30MG</td>
<td>Lupron Pediatric</td>
</tr>
<tr>
<td>0074-3346-03</td>
<td>LURPON DEPOT, 3MONTH 22.5 MG PDS KIT</td>
<td>Lupron Urology</td>
</tr>
<tr>
<td>0074-3473-03</td>
<td>LURPON DEPOT, 6MONTH, 45MG</td>
<td>Lupron Urology</td>
</tr>
</tbody>
</table>

### PRODUCTS STILL AVAILABLE

<table>
<thead>
<tr>
<th>NDC CODE</th>
<th>DESCRIPTION</th>
<th>LUPRON CLASSIFICATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>0074-3779-03</td>
<td>LURPON DEPOT PED, 3MONTH, 11.25MG</td>
<td>Lupron Pediatric</td>
</tr>
<tr>
<td>0074-2108-03</td>
<td>LURPON DEPOT PED, 1MONTH, 7.5MG</td>
<td>Lupron Pediatric</td>
</tr>
<tr>
<td>0074-2282-03</td>
<td>LURPON DEPOT PED, 1MONTH, 11.25 MG</td>
<td>Lupron Pediatric</td>
</tr>
<tr>
<td>0074-2440-03</td>
<td>LURPON DEPOT PED, 1MONTH, 15 MG</td>
<td>Lupron Pediatric</td>
</tr>
<tr>
<td>0074-3642-03</td>
<td>LURPON DEPOT, 1MONTH, 7.5 MG PDS KIT</td>
<td>Lupron Urology</td>
</tr>
<tr>
<td>0074-3683-03</td>
<td>LURPON DEPOT, 4MONTH, 30 MG PDS KIT</td>
<td>Lupron Urology</td>
</tr>
</tbody>
</table>
Insights on Recent Executive Orders from the Trump Administration

Brad Tallamy
Sr. Director, Government Affairs
Biosimilars are a promising product category, one that can provide patients and doctors with more affordable treatment options.

To date, there have been 28 approvals and 18 launches in the U.S. biosimilar market. As this market matures, its pipeline continues to grow. This reference guide is a useful tool to visualize and understand the current product landscape and potential future of this emerging market.

The market landscape chart is grouped by therapeutic class with FDA approved biosimilars (highlighted in light green) and biosimilars launched to date (highlighted in dark green) organized in columns under the relevant molecule and innovator product.

The market pipeline charts show products that have not received FDA approval and are expected to launch in one to four years. These charts suggest a bright future for biosimilars, as they document a large number of existing and new suppliers investing in biosimilars. The pipeline charts also capture the expansion of biosimilars into new therapeutic areas including ophthalmology, insulin, growth hormone, fertility and immunosuppressants.
# U.S. biosimilar market landscape

As of July 27, 2020

<table>
<thead>
<tr>
<th>CLASS</th>
<th>MOLECULE</th>
<th>SUPPORTIVE CARE</th>
<th>ONCOLOGY</th>
<th>TNF BLOCKERS</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLASS</td>
<td>MOLECULE</td>
<td>INNOVATOR</td>
<td>LAUNCHED</td>
<td>APPROVED</td>
</tr>
<tr>
<td>MOLECULE</td>
<td>Filgrastim</td>
<td>NEUPOGEN (Amgen)</td>
<td>ZARXIO (Sandoz) Sep 2015</td>
<td>NYVEPRIA (Pfizer) June 2020</td>
</tr>
<tr>
<td>MOLECULE</td>
<td>Epoetin</td>
<td>EPOGEN (Amgen)</td>
<td>RETACRIT (Pfizer/Vifor) Nov 2018</td>
<td></td>
</tr>
<tr>
<td>MOLECULE</td>
<td>Pegfilgrastim</td>
<td>NEULASTA (Amgen)</td>
<td>FULPHILA (Mylan) Jul 2018</td>
<td></td>
</tr>
<tr>
<td>MOLECULE</td>
<td></td>
<td></td>
<td>UDENYCA (Coherus) Jan 2019</td>
<td></td>
</tr>
<tr>
<td>MOLECULE</td>
<td></td>
<td></td>
<td>ZIEXTENZO (Sandoz Nov 2019</td>
<td></td>
</tr>
<tr>
<td>MOLECULE</td>
<td></td>
<td></td>
<td>NYVEPRIA (Pfizer) June 2020</td>
<td></td>
</tr>
<tr>
<td>MOLECULE</td>
<td>Rituximab</td>
<td>RITUXAN (Genentech)</td>
<td>TRUXIMA (Teva) Nov 2019</td>
<td>REMICADE (JnJ)</td>
</tr>
<tr>
<td>MOLECULE</td>
<td>Bevacizumab</td>
<td>AVASTIN (Genentech)</td>
<td>MVASI (Amgen) Jul 2019</td>
<td>ENBREL (AbbVie)</td>
</tr>
<tr>
<td>MOLECULE</td>
<td>Trastuzumab</td>
<td>HERCEPTIN (Genentech)</td>
<td>ZIRABEV (Pfizer) Jan 2020</td>
<td>Ongoing Litigation</td>
</tr>
<tr>
<td>MOLECULE</td>
<td></td>
<td></td>
<td>OGIVRI (Mylan) Nov 2019</td>
<td>Biosimilars referencing Humira will launch in 2023</td>
</tr>
<tr>
<td>MOLECULE</td>
<td></td>
<td></td>
<td>TRAZIMERA (Pfizer) Feb 2020</td>
<td></td>
</tr>
<tr>
<td>MOLECULE</td>
<td></td>
<td></td>
<td>HERZUMA (Teva) March 2020</td>
<td></td>
</tr>
<tr>
<td>MOLECULE</td>
<td></td>
<td></td>
<td>ONTRUZANT (Merck) Apr 2020</td>
<td></td>
</tr>
<tr>
<td>MOLECULE</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MOLECULE</td>
<td>Infliximab</td>
<td>INFLECTRA (Pfizer) Nov 2016</td>
<td>INFLEXIS (Merck) Jul 2018</td>
<td></td>
</tr>
<tr>
<td>MOLECULE</td>
<td>Etanercept</td>
<td>ERELZI (Sandoz) Aug 2016</td>
<td>AVSOLA (Amgen) July 2020</td>
<td></td>
</tr>
<tr>
<td>MOLECULE</td>
<td>Adalimumab</td>
<td>AMJEVITA (Mylan) Sep 2016</td>
<td>CYLTEZO (BI) Aug 2017</td>
<td></td>
</tr>
<tr>
<td>MOLECULE</td>
<td></td>
<td></td>
<td>HYRIMOZ (Sandoz) Oct 2018</td>
<td></td>
</tr>
<tr>
<td>MOLECULE</td>
<td></td>
<td></td>
<td>HADILIMA (Merck) Jul 2019</td>
<td></td>
</tr>
<tr>
<td>MOLECULE</td>
<td></td>
<td></td>
<td>ABRILADA (Pfizer) Nov 2019</td>
<td></td>
</tr>
<tr>
<td>MOLECULE</td>
<td></td>
<td></td>
<td>HULIO (Mylan) Jul 2020</td>
<td></td>
</tr>
</tbody>
</table>

*Not launching in the U.S.*
# U.S. biosimilar pipeline landscape

As of July 27, 2020

<table>
<thead>
<tr>
<th>CLASS</th>
<th>MOLECULE</th>
<th>INNOVATOR</th>
<th>PIPELINE</th>
</tr>
</thead>
<tbody>
<tr>
<td>SUPPORTIVE CARE</td>
<td>Filgrastim</td>
<td>NEUPOGEN (Amgen)</td>
<td>GRASTOFIL Accord Pending</td>
</tr>
<tr>
<td></td>
<td>Epoetin</td>
<td>EPOGEN (Amgen)</td>
<td>APO-EPO Apotex Ph III</td>
</tr>
<tr>
<td></td>
<td>Pegfilgrastim</td>
<td>NEULASTA (Amgen)</td>
<td>TPI-120 Amneal-Adello Ph I</td>
</tr>
<tr>
<td>ONCOLOGY</td>
<td>Rituximab</td>
<td>RITUXAN (Genentech)</td>
<td>ABP 798 Amgen Pending</td>
</tr>
<tr>
<td></td>
<td>Bevacizumab</td>
<td>AVASTIN (Genentech)</td>
<td>SB8 MerckSamsung Pending</td>
</tr>
<tr>
<td></td>
<td>Trastuzumab</td>
<td>HERCEPTIN (Genentech)</td>
<td>TRASTUZUMAB Apotex Pre-Clin</td>
</tr>
<tr>
<td>TNF BLOCKERS</td>
<td>Infliximab</td>
<td>REMICADE (JnJ)</td>
<td>NI-071 Sagent Ph III</td>
</tr>
<tr>
<td></td>
<td>Etanercept</td>
<td>ENBREL (Amgen)</td>
<td>CHS-0214 Coherus Ph III</td>
</tr>
<tr>
<td></td>
<td>Adalimumab</td>
<td>HUMIRA (AbbVie)</td>
<td>CHS-1420 Coherus Ph III</td>
</tr>
</tbody>
</table>

CONTINUED ON NEXT PAGE
U.S. biosimilar pipeline landscape
As of July 27, 2020

- **OPTAMOLOGY**
  - Ranibizumab
  - Aflibercept

- **IMMUNOSUPPRESSANT**
  - Eculizumab
  - Omalizumab
  - Natalizumab

- **BONE HEALTH**
  - Denosumab

---

**CLASS**

**MOLECULE**

**INNOVATOR**

**PIPELINE**

Manufacturer
Clinical Phase

**OPHTAMOLOGY**

- **LUCENTIS** (Genentech)
  - SB11
    - Samsung/Biogen
    - Ph III
  - M710
    - Momenta
    - Ph III
  - FYB201
    - Coherus (Famycon)
    - Ph III
  - CHS-3351
    - Coherus
    - Pre-Clin

- **EYLEA** (Regeneron)
  - ABP 938
    - Amgen
    - Ph III
  - ABP 959
    - Amgen
    - Ph III
  - ALT-L9
    - Alteogen
    - Pre-Clin

**IMMUNOSUPPRESSANT**

- **SOLIRIS** (Alexion)
  - SB12
    - Samsung
    - Ph I
  - ABP 959
    - Amgen
    - Ph III
  - GBR 310
    - Glenmark
    - Phase I

- **XOLAIR** (Alexion)
  - CT-P39
    - Celltrion
    - Ph I
  - SB12
    - Samsung
    - Ph I

- **TYSABRI** (Genentech)
  - FYB203
    - Famycon
    - Pre-Clin
  - GP2411
    - Sandoz/Hexal
    - Ph III
  - LY06006
    - Luye
    - Pre-Clin

---

**BONE HEALTH**

- **PROLIA** (Amgen)
  - GP2411
    - Sandoz/Hexal
    - Ph III
  - LY06006
    - Luye
    - Pre-Clin

**CONTINUED ON NEXT PAGE**
Connect with us

Find out how AmerisourceBergen is creating sustainability and longevity for biosimilars

Contact Sean and Michelle by sending an email to biosimilars@amerisourcebergen.com
Q & A

Please submit questions directly in the Skype window
We are united in our responsibility to create healthier futures.